EMJ Hematology 9 [Supplement 1] . 2021

In this issue

This review provides a summary of presentations from the 2020 virtual European Hematology Association (EHA)-Scientific Working Group (SWG) Scientific Meeting on Immunotherapy for Hematological Disorders. The session focussed on the T-cell Ig and mucin domain containing protein-3 (TIM-3) receptor and its potential as a new target for drug development in the treatment of patients with higher-risk myelodysplastic syndrome (MDS).

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.